Tue, Jul 22, 2014, 7:40 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Cadence Pharmaceuticals, Inc. Message Board

  • builder973 builder973 Aug 16, 2013 7:23 AM Flag

    This is #$%$

    There are several realities here. One, no one else has been able to produce Ofirmev. Second, while all of this legal mumbo jumbo goes on CADX can be cleaning up. This stuff can go on for years and years and meanwhile CADX gets to keep all the earnings, even if they have to spend a little on legal costs. If they win thelegal case this all goes away.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • dpca10@gmail.com dpca10 Aug 16, 2013 9:18 AM Flag

      I couldn't agree more, long term this shouldn't be an issue. However I wonder if this news was baked into the price drop we have seen or if a new wave of volatility will hit. I've been so surprised in the past how differently people interpret news, for all I know the expectation was that the uspto was expected to reject all claims initially and the fact that they only rejected some could be a win. I agree this becomes a non issue with an excela win, I just don't want to be off the bandwagon when the announcement comes

      • 1 Reply to dpca10
      • First the earnings miss, then the very odd Bloomberg piece a week ago about adverse events w/oral Acetamin., and now this non-final patent non-event. The 30% s.p. drop in 2 weeks seems to point to some concentrated shorting by someone with 'asymmetrical information' (my favorite term of art) into the USPTO announcement well before today's release.

        Sentiment: Hold

13.980.00(0.00%)Mar 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.